Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study
- PMID: 9400445
- DOI: 10.1016/s0022-5347(01)64022-9
Feasibility of transurethral resection for muscle infiltrating carcinoma of the bladder: long-term followup of a prospective study
Abstract
Purpose: We analyzed the long-term results of radical transurethral resection for the treatment of a large series of patients with muscle infiltrating bladder cancer entered into a prospective study to determine progression predictive factors.
Materials and methods: The study included 133 patients with invasive bladder cancer treated by radical transurethral resection who had negative biopsies of the muscle layer of the tumor bed. Followup was more than 5 years for all subjects and more than 10 years in 59 (44.4%). A comparative nonrandomized study was performed of a control group of 76 patients with invasive pathological stage pT2-3a, N0-3 bladder cancer treated by cystectomy. In those patients treated by radical transurethral resection univariate and multivariate analyses were performed to establish clinical progression predictive factors.
Results: At 5 and 10 years of followup cause specific survival rates were 80.5 and 74.5%, and bladder preservation rates were 82.7 and 79.6%, respectively. No significant difference was noted in terms of cause specific survival, with respect to the control group. The initial presence of associated bladder carcinoma in situ was the only independent progression predictive factor.
Conclusions: For patients with invasive bladder cancer radical transurethral resection is justified when the tumor is clinically limited to the muscular layer and when all biopsies of the periphery and depth of the tumor bed show muscular tissue negative for tumor cells. Patients with initial associated bladder carcinoma in situ should not be excluded from this treatment but endovesical bacillus Calmette-Guerin immunotherapy should be administered and a closer followup is recommended.
Similar articles
-
Feasibility of radical transurethral resection as monotherapy for selected patients with muscle invasive bladder cancer.J Urol. 2010 Aug;184(2):475-80. doi: 10.1016/j.juro.2010.04.008. Epub 2010 Jun 17. J Urol. 2010. PMID: 20620402 Clinical Trial.
-
Survival rates after radical cystectomy according to tumor stage of bladder carcinoma at first presentation.Urol Int. 2004;72(2):103-11. doi: 10.1159/000075962. Urol Int. 2004. PMID: 14963349
-
Feasibility of transurethral resection for muscle-infiltrating carcinoma of the bladder: prospective study.J Urol. 1992 Jun;147(6):1513-5. doi: 10.1016/s0022-5347(17)37612-7. J Urol. 1992. PMID: 1593678
-
The treated natural history of high risk superficial bladder cancer: 15-year outcome.J Urol. 1997 Jul;158(1):62-7. doi: 10.1097/00005392-199707000-00017. J Urol. 1997. PMID: 9186324 Review.
-
Intravesical Therapy for the Treatment of Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.J Urol. 2017 May;197(5):1189-1199. doi: 10.1016/j.juro.2016.12.090. Epub 2016 Dec 24. J Urol. 2017. PMID: 28027868
Cited by
-
Bladder preservation in muscle-invasive bladder cancer: a comprehensive review.Int Braz J Urol. 2020 Mar-Apr;46(2):169-184. doi: 10.1590/S1677-5538.IBJU.2020.99.01. Int Braz J Urol. 2020. PMID: 31961624 Free PMC article. Review.
-
Radical transurethral resection alone, robotic or partial cystectomy, or extended lymphadenectomy: can we select patients with muscle invasion for less or more surgery?Urol Clin North Am. 2015 May;42(2):189-99, viii. doi: 10.1016/j.ucl.2015.02.003. Epub 2015 Feb 28. Urol Clin North Am. 2015. PMID: 25882561 Free PMC article. Review.
-
Urothelial carcinoma management in elderly or unfit patients.EJC Suppl. 2016 Mar;14(1):1-20. doi: 10.1016/j.ejcsup.2016.01.001. Epub 2016 Mar 22. EJC Suppl. 2016. PMID: 27358584 Free PMC article. No abstract available.
-
[Alternatives to cystectomy].Urologe A. 2015 Apr;54(4):504-9. doi: 10.1007/s00120-015-3775-6. Urologe A. 2015. PMID: 25895563 Review. German.
-
[Organ-sparing treatment of bladder cancer].Urologe A. 2016 May;55(5):609-14. doi: 10.1007/s00120-016-0086-5. Urologe A. 2016. PMID: 27119956 Review. German.
MeSH terms
LinkOut - more resources
Full Text Sources
Medical